Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease.
We begin with a commentary from Eleni Armeni and Ashley Grossman on seliciclib, a potential new treatment for patients with Cushing’s disease. Following this, Fernandez et al. disseminate our current understanding of metabolic dysfunction-associated fatty liver disease.
In the area of diabetes, Calvo et al. review the role of the placenta in the development of gestational diabetes from a molecular perspective. Stachteas and colleagues provide an overview of bexagliflozin, an orally administered sodium glucose transporter 2 inhibitor recently approved by the US Food and Drug Administration for the treatment of type 2 diabetes (T2D) as an adjunct therapy to diet and exercise in the USA.
On the topic of obesity and oral health, Checa-Ros et al. provide a review of the role of adipokines in the pathophysiology and progression of periodontitis with a focus on their impact on inflammation and the molecular mechanisms.
Our attention next shifts to pituitary disorders. Injectable somatostatin receptor ligands (iSRLs) are the most common treatment for the management of acromegaly; however, patient satisfaction rates are suboptimal. Injections can result in local erythema, discomfort and subcutaneous nodule formation, combined with the inconvenience of attending either primary or secondary care medical facilities for the injections. McLaren et al. review oral octreotide capsules and paltusotine as potential treatment options for patients with controlled disease on iSRLs. We then have a review from Uygur et al. summarizing the clinical pharmacological data on the development and clinical use of oral octreotide capsules for long-term maintenance treatment in patients with acromegaly.
Pivonello et al. provide a review focussing on osilodrostat, a novel potent oral steroidogenesis inhibitor, which has recently been approved for the treatment of adult patients with endogenous Cushing’s syndrome.
We then include two original research articles. In the first, Siminerio and colleagues share the results of a feasibility study that evaluated an approach to support insulin dose adjustment in individual patients with T2D using a mobile titration application. The second investigates the challenges in risk stratification of solid atypical mixed echogenicity thyroid nodules.
The issue concludes with an interesting case report. Dextre-Espinoza et al. present a case of panhypopituitarism in a patient with burkitt lymphoma.
We would like to thank all those who contributed the insightful and informative articles included in this edition. A special thanks also goes to our editorial board for their continuing support and guidance. We are also grateful to all organizations and media partners for their ongoing support. We hope that you find these topical articles interesting and informative.
John Doupis
Dr John Doupis is a former clinical research fellow of the Joslin Diabetes Center, Harvard Medical School, in Boston, MA, USA and scientific partner in Beth Israel Deaconess Foot Center Harvard Medical School, Boston, MA. Currently, he is directing the Diabetes Division and Clinical Research Center of Iatriko P. Falirou Medical Center in Athens, Greece. He has served as a principal investigator in many multicentre phase I, II, III and IV clinical trials, most of which have been published in international journals or presented at congresses. He is a registered reviewer and a member of the editorial board for many major diabetes medical journals. He has given numerous lectures in national and international congresses, presenting over 200 abstracts. His special areas of interest are diabetes and its complications, especially obesity, diabetic neuropathy, diabetic foot, as well as the glucose sensing technologies and insulin pumps. In these fields, he has published more than 50 papers in international medical journals, having more than 1,500 citations.
